| Human immunodeficiency virus I infection
Rukobia vs Sunlenca
Side-by-side clinical, coverage, and cost comparison for human immunodeficiency virus i infection.Deep comparison between: Rukobia vs Sunlenca with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsSunlenca has a higher rate of injection site reactions vs Rukobia based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Sunlenca but not Rukobia, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Rukobia
Sunlenca
At A Glance
Oral
Twice daily
HIV-1 attachment inhibitor
SC injection
Every 6 months
HIV-1 capsid inhibitor
Indications
- Human immunodeficiency virus I infection
- Human immunodeficiency virus I infection
Dosing
Human immunodeficiency virus I infection 600 mg orally twice daily with or without food; swallow tablets whole, do not chew, crush, or split.
Human immunodeficiency virus I infection (Initiation Option 1) Day 1: 927 mg SC injection (2 x 1.5 mL) plus 600 mg oral (2 x 300 mg tablets); Day 2: 600 mg oral (2 x 300 mg tablets); then 927 mg SC every 6 months (26 weeks) for maintenance.
Human immunodeficiency virus I infection (Initiation Option 2) Days 1 and 2: 600 mg oral (2 x 300 mg tablets); Day 8: 300 mg oral (1 x 300 mg tablet); Day 15: 927 mg SC injection (2 x 1.5 mL); then 927 mg SC every 6 months (26 weeks) for maintenance.
Contraindications
- Previous hypersensitivity to fostemsavir or any component of RUKOBIA
- Coadministration with strong CYP3A inducers, including enzalutamide, carbamazepine, phenytoin, rifampin, mitotane, and St John's wort (Hypericum perforatum)
- Concomitant use of strong CYP3A inducers
Adverse Reactions
Most common (>=2%) Nausea, diarrhea, headache, abdominal pain, dyspepsia, fatigue, rash, sleep disturbance, immune reconstitution inflammatory syndrome, somnolence, vomiting
Serious Immune reconstitution inflammatory syndrome, QTc prolongation, hepatic transaminase elevations in patients with hepatitis B or C virus co-infection
Most common (>=3%) Injection site reactions, nausea
Serious Grade 3 injection site reactions (erythema, pain, swelling)
Postmarketing Injection site necrosis
Pharmacology
HIV-1 attachment inhibitor; fostemsavir is a prodrug hydrolyzed to temsavir, which binds directly to the gp120 subunit of the HIV-1 envelope glycoprotein and selectively inhibits the interaction between the virus and cellular CD4 receptors, preventing viral attachment and subsequent entry into host cells.
Lenacapavir is a multistage, selective HIV-1 capsid inhibitor that directly binds to capsid protein (p24) subunits in hexamers, inhibiting multiple essential steps of the viral lifecycle including capsid-mediated nuclear uptake of proviral DNA, virus assembly and release, and capsid core formation.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Rukobia
- Covered on 5 commercial plans
- PA (9/12) · Step Therapy (9/12) · Qty limit (11/12)
Sunlenca
- Covered on 5 commercial plans
- PA (10/12) · Step Therapy (9/12) · Qty limit (11/12)
UnitedHealthcare
Rukobia
- Covered on 4 commercial plans
- PA (4/8) · Step Therapy (0/8) · Qty limit (2/8)
Sunlenca
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (0/8)
Humana
Rukobia
- Covered on 0 commercial plans
- PA (1/3) · Step Therapy (1/3) · Qty limit (3/3)
Sunlenca
- Covered on 0 commercial plans
- PA (1/3) · Step Therapy (0/3) · Qty limit (3/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
Cost estimate not availableGood Days: HIV, AIDS Treatment & Prevention
Commercial or private insurance
Medicare, Medicaid, VA, TRICARE
$0/fillfill
Gilead Advancing Access Co-Pay Program: SunlencaCommercial or private insurance
Medicare, Medicaid, VA, TRICARE
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
RukobiaView full Rukobia profile
SunlencaView full Sunlenca profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.